Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity

2 months ago 31

Lee Samaha, The Motley Fool

Fri, July 24, 2026 astatine 9:33 AM CDT 3 min read

Shareholders successful biotechnology, beingness sciences, and diagnostics solutions institution Danaher (NYSE: DHR) person had an absorbing week. Their banal crashed aboriginal successful the week connected the merchandise of its second-quarter earnings, lone to retrieve somewhat done the week and commencement Friday greeting having declined 12.1% connected the week.

Danaher mixed net study

Investors tin beryllium forgiven for wondering wherefore the banal declined aft the company's second-quarter net bushed estimates and absorption raised its full-year net per stock (EPS) guidance to $8.45-$8.60 from a $8.35-$8.55 previously.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

The reply lies successful the information that $0.07 to $0.08 of the summation successful guidance comes from the earlier-than-expected acquisition of the aesculapian exertion institution Masimo. In addition, Danaher reduced its full-year halfway income maturation expectations successful its highest borderline business, biotechnology.

Data source: Company presentations. Table by the author.

What the guidance alteration means

It's not a immense alteration successful wide institution income maturation expectations. Still, the simplification successful maturation expectations for the biotechnology could interaction full-year nett borderline expectations.

The disappointing quality successful biotechnology came down to consumables income coming successful "below our expectations arsenic a fewer ample shipments for programs astatine our commercialized customers moved retired of the quarter. To springiness you immoderate further color, this was a displacement successful shipment timing astatine a fewer ample commercialized cause manufacturers for molecules that were specced into" according to CEO Rainer Blair connected the net call.

A idiosyncratic    astatine  work.

Image source: Getty Images.

Analysts were speedy to inquire wherefore the shipments wouldn't simply determination to the 3rd and 4th quarters, with Blair outlining that a fewer chromatography resin shipments had moved retired of the year.

There's a bully crushed to judge the shipments volition proceed, arsenic shipments tin beryllium lumpy successful biotechnology. The sell-off appears to beryllium a important overreaction to an different affirmative report. If you similar the banal long-term, past it could beryllium a bully clip to prime immoderate up.

Read Entire Article